Tag: erlotinib

Living Longer: Stage 4 Lung Adenocarcinoma EGFR Mutation positive

Living Longer: Stage 4 Lung Adenocarcinoma EGFR Mutation positive

Introduction Firstly, with optimal palliative chemotherapy treatment for stage 4 lung cancer, the average survival is slightly under a year; 7.4 months - 8.1 months (Schiller JH, 2002), which doubled the average survival with just best supportive care, 3.9 months. Although improvement in survival was achieved with chemotherapy, it seemed like chemotherapy alone had reached … Continue reading Living Longer: Stage 4 Lung Adenocarcinoma EGFR Mutation positive